Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating)'s share price fell 6% during mid-day trading on Monday . The stock traded as low as $0.11 and last traded at $0.11. 4,525,740 shares traded hands during mid-day trading, a decline of 19% from the average session volume of 5,556,676 shares. The stock had previously closed at $0.12.
Analyst Upgrades and Downgrades
Separately, HC Wainwright lowered their price objective on Timber Pharmaceuticals from $1.50 to $1.00 and set a "buy" rating on the stock in a report on Monday, August 29th.
Get Timber Pharmaceuticals alerts:Timber Pharmaceuticals Price Performance
The stock has a fifty day moving average of $0.16 and a two-hundred day moving average of $0.25. The stock has a market capitalization of $14.57 million, a price-to-earnings ratio of -0.33 and a beta of 0.27. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 1.30.
Timber Pharmaceuticals (NYSE:TMBR – Get Rating) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.05). Timber Pharmaceuticals had a negative return on equity of 228.75% and a negative net margin of 1,274.17%. As a group, equities research analysts forecast that Timber Pharmaceuticals, Inc. will post -0.17 earnings per share for the current year.Institutional Trading of Timber Pharmaceuticals
An institutional investor recently raised its position in Timber Pharmaceuticals stock. Renaissance Technologies LLC boosted its holdings in shares of Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating) by 37.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 871,237 shares of the company's stock after buying an additional 238,663 shares during the quarter. Renaissance Technologies LLC owned approximately 1.36% of Timber Pharmaceuticals worth $335,000 at the end of the most recent reporting period. 5.78% of the stock is currently owned by institutional investors and hedge funds.
Timber Pharmaceuticals Company Profile
(Get Rating)
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs.
Featured Articles
- Get a free copy of the StockNews.com research report on Timber Pharmaceuticals (TMBR)
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
Receive News & Ratings for Timber Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Timber Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.